Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3925843 | 0.98 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7702540 | 0.98 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL11431122 | 0.85 | DAO (0.60) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL6069428 | 0.84 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL444120 | 0.83 | DAO (0.58) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL26352125 | 0.82 | GRIA1 (0.51) | DAOPOLB | |
| SCHEMBL11691177 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7596452 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL14701887 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL2924922 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002030886-A2 | HETEROCYCLIC ANGIOGENESIS INHIBITORS | MATTHEWS BARRY R (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20130158092-A1 | New Oral Formulation | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120071537-A1 | New Oral Formulation | DE BRUIJN KAREL (FR) | 2012-03-22 | — | — | US | disclosed |
| EP-2358702-A2 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK Holdings Co., Ltd. (KR) | 2011-08-24 | — | — | EP | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1902053-B1 | BENZOIMIDAZOLONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010044585-A2 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-22 | — | — | WO | disclosed |
| EP-1960396-B1 | CARBAMATE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1104289-A2 | NEW ORAL FORMULATION FOR 5-HT4 AGONISTS OR ANTAGONISTS | Novartis AG (CH) | 2001-06-06 | — | — | EP | disclosed |
| US-6117882-A | 5-HT4 agonists and antagonists | ELI LILLY AND COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-6069152-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| WO-2000010526-A2 | NEW ORAL FORMULATION FOR 5-HT4 AGONISTS OR ANTAGONISTS | NOVARTIS AG (CH) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999017772-A1 | 5HT4 AGONISTS AND ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908459-A1 | 5-HT4 Agonists and antagonists | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5811432-A | Azaoxindole derivatives | PFIZER INC (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1994000454-A1 | BENZIMIDAZOLE COMPOUNDS | G.D. SEARLE & CO. (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1991009598-A1 | AZAOXINDOLE DERIVATIVES | PFIZER INC. (US) | 1991-07-11 | — | — | WO | disclosed |
| EP-0436333-A2 | Azaoxindole derivatives | PFIZER INC. (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071537-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | DAO 2583/4885POLB 4732/4885MEN1 2219/4885 |
| US-20130158092-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | DAO 2583/4885POLB 4732/4885MEN1 2219/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | DAO 2300/4885POLB 2777/4885MEN1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.